Dose 1: 17Jun2021 and dose 2: 08Aug2021; Tremors (hands and heads); Involuntary and sudden movements in limbs, especially when I'm lying down trying to sleep; muscle stiffness; weakiness and heaviness in my legs; physical exhaustion and chronic fatigue/ Extreme tiredness after doing routine; pain; mental lapses, memory loss; Blurrier-than-normal vision; shortness of breath; Tachycardia and chest pain; Tachycardia and chest pain; pain and difficulty writing; Difficulty walking (mainly to get up and when starting to walk); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 40 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 08Aug2021 18:30 (Lot number: EW0127) at the age of 40 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "stevens -Johnson syndrome", start date: 21Mar2011, stop date: Apr2011, notes: Pertinent details: 5 days hospitalization with immunoglobulin treatment.; "annual plaques" (unspecified if ongoing), notes: From 2002-2003 onwards - back (cervical, thoracic and lumbar) and hips every few years. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1 Time:18:30. Anatomical site of injection: Left arm. Route of administration: intramuscular. Batch/lot number: EN0202), administration date: 17Jun2021, when the patient was 40 years old, for Covid-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown", described as "Dose 1: 17Jun2021 and dose 2: 08Aug2021"; TREMOR (non-serious), outcome "unknown", described as "Tremors (hands and heads)"; DYSKINESIA (non-serious), outcome "unknown", described as "Involuntary and sudden movements in limbs, especially when I'm lying down trying to sleep"; MUSCULOSKELETAL STIFFNESS (non-serious), outcome "unknown", described as "muscle stiffness"; ASTHENIA (non-serious), outcome "unknown", described as "weakiness and heaviness in my legs"; FATIGUE (non-serious), outcome "unknown", described as "physical exhaustion and chronic fatigue/ Extreme tiredness after doing routine"; PAIN (non-serious), outcome "unknown", described as "pain"; AMNESIA (non-serious), outcome "unknown", described as "mental lapses, memory loss"; VISUAL IMPAIRMENT (non-serious), outcome "unknown", described as "Blurrier-than-normal vision"; DYSPNOEA (non-serious), outcome "unknown", described as "shortness of breath"; CHEST PAIN (non-serious), TACHYCARDIA (non-serious), outcome "unknown" and all described as "Tachycardia and chest pain"; MOBILITY DECREASED (non-serious), outcome "unknown", described as "pain and difficulty writing"; GAIT DISTURBANCE (non-serious), outcome "unknown", described as "Difficulty walking (mainly to get up and when starting to walk)". The events "tremors (hands and heads)", "involuntary and sudden movements in limbs, especially when i'm lying down trying to sleep", "muscle stiffness", "weakiness and heaviness in my legs", "physical exhaustion and chronic fatigue/ extreme tiredness after doing routine", "pain", "mental lapses, memory loss", "blurrier-than-normal vision", "shortness of breath", "tachycardia and chest pain", "tachycardia and chest pain" and "pain and difficulty writing" were evaluated at the physician office visit.  No follow-up attempts are possible. No further information is expected.